260 results on '"Burger, Judith A."'
Search Results
2. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
3. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
4. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
5. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
6. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies
7. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
8. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
9. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
10. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection
11. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
12. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
13. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
14. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
15. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
16. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
17. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
18. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses
19. Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers
20. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
21. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
22. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
23. Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers
24. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
25. Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
26. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
27. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies
28. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle
29. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence
30. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
31. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
32. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
33. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
34. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual
35. HIV-1 neutralizing antibodies induced by native-like envelope trimers
36. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies
37. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
38. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
39. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
40. Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability
41. CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer
42. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
43. Mapping the antigenic diversification of SARS-CoV-2
44. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
45. Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection
46. HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies
47. Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Patients With Inborn Errors of Immunity
48. Low Incidence of HIV-1 Superinfection Even After Episodes of Unsafe Sexual Behavior of Homosexual Men in the Amsterdam Cohort Studies on HIV Infection and AIDS
49. Absence of HIV-1 Superinfection 1 Year after Infection between 1985 and 1997 Coincides with a Reduction in Sexual Risk Behavior in the Seroincident Amsterdam Cohort of Homosexual Men
50. A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.